Monoclonal antibody‐based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER

Objectives Monoclonal antibody‐based of cancer therapy has been considered as one of the most successful therapeutic strategies for both haematologic malignancies and solid tumours in the last two decades. Epidermal growth factor receptor ( EGFR ) family signalling pathways play a key role in the regulation of cell proliferation, survival and differentiation. Hence, anti‐ EGFR family m A bs is one of the most promising approaches in cancer therapy. Key findings Here, recent advances in anti‐ EGFR m A b including approved or successfully tested in preclinical and clinical studies have been reviewed. Although we focus on monoclonal antibodies against the EGF receptor, but the mechanisms underlying the effects of EGFR ‐specific m A b in cancer therapy, to some extend the resistance to existing anti‐ EGFR therapies and some therapeutic strategies to overcome resistance such as combination of m A bs on different pathways are briefly discussed as well. Summary The EGFR family receptors, is considered as an attractive target for m A b development to inhibit their consecutive activities in tumour growth and resistance. However, due to resistance mechanisms, the combination therapies may become a good candidate for targeting EGFR family receptors.